NEW YORK (GenomeWeb News) – Caprotec Bioanalytics said today that it will collaborate with a division of Merck KGaA to identify protein and drug interactions using its mass spectrometry technology.
Under the agreement, Caprotec will use its Capture Compound Mass Spectrometry technology for a research project for Merck Serono. Berlin-based Caprotec will be paid research fees and milestone payments for product development, it said.
The firm’s CCMS technology consists of small, tri-functional molecules that allow researchers to isolate proteins directly from biological samples that may then be isolated and characterized. The technology can be used in proteomics, drug development, and biomarker research, the company said.
Financial terms of the agreement were not released.